Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

CONCLUSIONSA substantial proportion of drug‐related dermatologic AEs occur after the traditional dose‐limiting toxicity monitoring period of phase 1 clinical trials. Future designs should account for late toxicities. Cancer 2016. © 2016 American Cancer Society.

Source: Cancer - February 25, 2016 Category: Cancer & Oncology Authors: Alexander Drilon, Anne A. Eaton, Katja Schindler, Mrinal M. Gounder, David R. Spriggs, Pamela Harris, S. Percy Ivy, Alexia Iasonos, Mario E. Lacouture, David M. Hyman Tags: Original Article Source Type: research